Rep. Marjorie Taylor Greene Purchases Shares of AbbVie Inc. (NYSE:ABBV)

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on August 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in AbbVie stock on August 4th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 8/4/2025.
• Purchased $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 8/4/2025.
• Purchased $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 7/15/2025.
• Purchased $1,001 – $15,000 in shares of Palantir Technologies (NASDAQ:PLTR) on 7/15/2025.
• Purchased $1,001 – $15,000 in shares of Tractor Supply (NASDAQ:TSCO) on 6/17/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 6/17/2025.
• Sold $1,001 – $15,000 in shares of lululemon athletica (NASDAQ:LULU) on 6/17/2025.
• Purchased $1,001 – $15,000 in shares of Netflix (NASDAQ:NFLX) on 6/6/2025.
• Purchased $1,001 – $15,000 in shares of Applied Materials (NASDAQ:AMAT) on 6/6/2025.
• Purchased $1,001 – $15,000 in shares of Gilead Sciences (NASDAQ:GILD) on 6/6/2025.

AbbVie Trading Down 0.2%

NYSE ABBV opened at $206.23 on Tuesday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The firm has a market cap of $364.32 billion, a PE ratio of 98.21, a P/E/G ratio of 1.33 and a beta of 0.50. AbbVie Inc. has a one year low of $163.81 and a one year high of $218.66. The firm’s fifty day moving average is $191.42 and its two-hundred day moving average is $192.47.

AbbVie (NYSE:ABBV) last issued its earnings results on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing the consensus estimate of $3.24 by ($0.27). AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm had revenue of $15.42 billion during the quarter, compared to analysts’ expectations of $14.93 billion. During the same period in the previous year, the firm earned $2.65 EPS. The firm’s revenue was up 6.6% on a year-over-year basis. Analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, August 15th. Investors of record on Tuesday, July 15th were given a $1.64 dividend. The ex-dividend date was Tuesday, July 15th. This represents a $6.56 annualized dividend and a yield of 3.2%. AbbVie’s dividend payout ratio is 312.38%.

Hedge Funds Weigh In On AbbVie

Several institutional investors and hedge funds have recently modified their holdings of ABBV. TD Capital Management LLC increased its position in AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after purchasing an additional 58 shares during the last quarter. Marshall & Sullivan Inc. WA acquired a new position in AbbVie during the second quarter worth approximately $25,000. Abound Financial LLC acquired a new position in AbbVie during the first quarter worth approximately $30,000. Spurstone Advisory Services LLC acquired a new position in AbbVie during the second quarter worth approximately $28,000. Finally, Cypress Capital Management LLC WY acquired a new position in AbbVie during the first quarter worth approximately $35,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Daiwa America upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 7th. Guggenheim boosted their price objective on shares of AbbVie from $216.00 to $227.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Cantor Fitzgerald began coverage on shares of AbbVie in a report on Tuesday, April 22nd. They set an “overweight” rating and a $210.00 price objective on the stock. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 22nd. Finally, Piper Sandler began coverage on shares of AbbVie in a report on Tuesday, August 12th. They set an “overweight” rating and a $231.00 price objective on the stock. Six research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and five have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $214.95.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 13,295 shares of the stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the completion of the sale, the executive vice president owned 58,247 shares of the company’s stock, valued at $11,562,611.97. This represents a 18.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the sale, the executive vice president directly owned 177,292 shares of the company’s stock, valued at $35,178,278.64. The trade was a 19.29% decrease in their position. The disclosure for this sale can be found here. 0.08% of the stock is owned by corporate insiders.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia’s 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 14th Congressional District. She declared candidacy for the 2026 election.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.